AHA GUIDELINES Bundle (free trial)

ST-Elevation Myocardial Infarction

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/104088

Contents of this Issue

Navigation

Page 9 of 29

Treatment Reperfusion at a Non–PCI-Capable Hospital Fibrinolytic Therapy When There Is An Anticipated Delay To Performing Primary PCI Within 120 Minutes Of FMC (Table 4) ÎÎIn the absence of contraindications, fibrinolytic therapy should be given to patients with STEMI and onset of ischemic symptoms within the previous 12 hours when it is anticipated that primary PCI cannot be performed within 120 minutes of FMC. (I-A) ÎÎIn the absence of contraindications and when PCI is not available, fibrinolytic therapy is reasonable for patients with STEMI if there is clinical and/or ECG evidence of ongoing ischemia within 12-24 hours of symptom onset and a large area of myocardium at risk or hemodynamic instability. (IIa-C) ÎÎFibrinolytic therapy should NOT be administered to patients with ST depression except when a true posterior (inferobasal) MI is suspected or when associated with ST elevation in lead aVR. (III-B: Harm) Table 4. Indications for Fibrinolytic Therapy When There Is a > 120-Minute Delay From FMC to Primary PCI COR Ischemic symptoms <12 h Evidence of ongoing ischemia 12-24 h after symptom onset and a large area of myocardium at risk or hemodynamic instability ST depression, except if true posterior (inferobasal) MI is suspected or when associated with ST elevation in lead aVR 8 LOE I A IIa C III: Harm B

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - ST-Elevation Myocardial Infarction